Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02091245 · ClinicalTrials.gov registry record · Phase 1
Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapsed Childhood ALL and AML
A Phase 1 study of Refractory Acute Lymphoblastic Leukemia (ALL) and Relapsed Acute Lymphoblastic Leukemia (ALL), sponsored by Dana-Farber Cancer Institute.
- Active
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
- 10
- Study locations
NCT02091245 is a Phase 1 study of Refractory Acute Lymphoblastic Leukemia (ALL) and Relapsed Acute Lymphoblastic Leukemia (ALL) that is active but no longer recruiting, run by Dana-Farber Cancer Institute. The registered enrollment target is 16 participants. The trial reports 10 study locations across 9 states.
The verdict
NCT02091245, a Phase 1 study of Refractory Acute Lymphoblastic Leukemia (ALL) and Relapsed Acute Lymphoblastic Leukemia (ALL), is active but no longer recruiting, sponsored by Dana-Farber Cancer Institute.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
- 10
- Study locations
Study Summary
This research study involves participants who have acute lymphoblastic or acute myelogenous leukemia that has relapsed or has become resistant (or refractory) to standard therapies. This research study is evaluating a drug called KPT-330. Laboratory and other studies suggest that the study drug, KPT-330, may prevent leukemia cells from growing and may lead to the destruction of leukemia cells. It is thought that KPT-330 activates cellular processes that increase the death of leukemia cells. The main goal of this study is to evaluate the side effects of KPT-330 when it is administered to children and adolescents with relapsed or refractory leukemia.
Conditions Studied
Interventions
- DRUG KPT-330
Study Locations (10)
Massachusetts
- Boston Children's Hospital - Boston
- Dana-Farber Cancer Institute - Boston
California
- UCSF - San Francisco
Colorado
- Children's Hospital Colorado - Aurora
Georgia
- Children's Healthcare of Atlanta - Atlanta
New York
- Columbia University Medical Center - New York
Pennsylvania
- Children's Hospital of Philadelphia - Philadelphia
Texas
- Texas Children's Hospital - Houston
Washington
- Seattle Children's Hospital - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2014-03 |
| Est. Completion | 2026-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02091245
The ClinicalTrials.gov registry entry for NCT02091245 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 9 conditions, with Refractory Acute Lymphoblastic Leukemia (ALL) appearing as the primary indexed condition, and to 1 intervention - of which KPT-330 is the first listed.
NCT02091245 reports 10 study locations spanning 9 distinct geographic areas - top geographies include Massachusetts, California, Colorado.
Frequently Asked Questions
What is clinical trial NCT02091245 about?
NCT02091245 is a clinical study titled "Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapsed Childhood ALL and AML". This research study involves participants who have acute lymphoblastic or acute myelogenous leukemia that has relapsed or has become resistant (or refractory) to standard therapies. This research study is evaluating a drug called KPT-330. Laboratory and other studies suggest that the study drug, KPT...
What is the current status of trial NCT02091245?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2014-03. Estimated completion is 2026-06.
What conditions does trial NCT02091245 study?
This clinical trial studies the following conditions: Refractory Acute Lymphoblastic Leukemia (ALL), Relapsed Acute Lymphoblastic Leukemia (ALL), Relapsed Acute Myelogenous Leukemia (AML), Refractory Acute Myelogenous Leukemia (AML), Relapsed Mixed Lineage Leukemia.
What interventions are being tested in trial NCT02091245?
The interventions under investigation include: KPT-330 (DRUG).
Who is sponsoring clinical trial NCT02091245?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02091245 being conducted?
This trial has 10 study locations across California, Colorado, Georgia, Massachusetts, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Refractory Acute Lymphoblastic Leukemia (ALL)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Refractory Acute Lymphoblastic Leukemia (ALL)
All registered trials for this condition
Relapsed Acute Lymphoblastic Leukemia (ALL)
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.